Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlycoMimetics Incorporated
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed HR+ metastatic breast cancer, currently stable or minimally progressive on current endocrine-based therapy.
Continuing on current endocrine-based therapy with an aromatase inhibitor, selective estrogen receptor degrader, or selective estrogen receptor modulator; and must be medically eligible to remain on this therapy during the treatment period.
You may not be if
Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
Subjects who are pregnant or breastfeeding
Concurrent treatment with any cytotoxic chemotherapy agent or other targeted therapies including HER2 targeting therapies
Currently receiving, or less than 28 days since ending treatment on another investigational drug.
Clinically significant cardiovascular disease.
Abnormal liver function.
Any medical, psychiatric, or other condition which, in the opinion of the investigator, is likely to interfere with trial completion, assessments, or interpretation of trial results, or otherwise would make the subject an inappropriate subject for this trial.
Clareo Health | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
